TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7801861
Drug: Low-dose combinations
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combinations
Study: 2139940
Drug: imipenem-cilastatin 500
Normalized name: imipenem-cilastatin 500 mg-500 mg injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: imipenem-cilastatin 500 mg 8-hourly
Study: 2139940
Drug: cefotaxime 1
Normalized name: cefotaxime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cefotaxime 1 g 6-hourly combined with amikacin 5 mg/kg 8-hourly
Study: 29561515
Drug: Lidocaine (0.2-0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (0.2-0.4 mg/kg) coadministered with amikacin (15 mg/kg)
Study: 29561515
Drug: Amikacin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin (15 mg/kg) without lidocaine
Study: 25454409
Drug: 3-item craving
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-item craving scale administered weekly
Study: 22702067
Drug: GnRH analogues
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH analogues pre-treatment before laparoscopic myomectomy (LM)
Study: 22702067
Drug: GnRH analogues
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH analogues pre-treatment before open laparotomic myomectomy (OM)
Study: 22702067
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no pre-treatment) for laparoscopic myomectomy (LM)
Study: 20580216
Drug: Formoterol fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol fumarate 12 microg twice-daily plus Tiotropium 18 microg once-daily (FOR-TIO)
Study: 20580216
Drug: Formoterol fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol fumarate 12 microg twice-daily plus placebo (FOR-PLA)
Study: 9121622
Drug: Transcranial magnetic
Normalized name: transcranial magnetic stimulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial magnetic stimulation (TMS) as add‐on therapy to standard antidepressive medication
Study: 9121622
Drug: Standard antidepressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antidepressive medication only
Study: 7117166
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of 5‐isosorbide mononitrate (5‐ISMN)
Study: 7117166
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of 5‐isosorbide mononitrate (5‐ISMN)
Study: 7117166
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of 5‐isosorbide mononitrate (5‐ISMN) three times daily for four weeks
Study: 7117166
Drug: Chronic administration
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic administration of high doses of 5‐ISMN
Study: 28509813
Drug: Fennel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fennel (100 mg, 2 capsules per day for 8 weeks)
Study: 25975205
Drug: Variable dose
Normalized name: methohexital
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Variable dose warfarin (target INR 2.0-2.5), treated for 28 ± 2 days
Study: 25975205
Drug: Fixed low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fixed low-dose warfarin (1 mg daily starting 7 days preoperatively), treated for 28 ± 2 days
Study: 25975205
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg daily starting on the day of surgery), treated for 28 ± 2 days
Study: 24190687
Drug: Guided strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided strength training program (twice weekly for 19 weeks)
Study: 21285171
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg eow
Study: 15156251
Drug: Topical Aescin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Aescin + essential phospholipids (AEPL) gel applied for 2 weeks, three times daily
Study: 2060547
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg o.d.
Study: 30715153
Drug: Pembrolizumab 2
Normalized name: pembrolizumab 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 2 mg/kg every 3 weeks, 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks until disease progression, intolerable toxicity, or patient/investigator decision to withdraw
Study: 29378603
Drug: Chemotherapy following
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy following ESD
Study: 20627022
Drug: Flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen axetil 1 mg/kg intravenous 15 minutes before induction of general anesthesia (Group B)
Study: 18343243
Drug: MLR methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLR methylphenidate 20 mg QD
Study: 18343243
Drug: OROS methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS methylphenidate 18 mg QD
Study: 15841929
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol 100 microg every 2 hours
Study: 15841929
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 100 microg every 2 hours
Study: 12109627
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of oral 17beta E2 daily (group A)
Study: 12109627
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg E2 daily plus 5 mg daily oral dydrogesterone (group B)
Study: 12109627
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg E2 and 10 mg dydrogesterone (group C)
Study: 10674879
Drug: CEF (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEF (cyclophosphamide 100 mg m(‐2) p.o. days 1‐14, fluorouracil 500 mg m(‐2) i.v. days 1 and 8, epirubicin 30 mg m(‐2) i.v. days 1 and 8)
Study: 10674879
Drug: CNF (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNF (cyclophosphamide 100 mg m(‐2) p.o. days 1‐14, fluorouracil 500 mg m(‐2) i.v. days 1 and 8, mitoxantrone 6 mg m(‐2) i.v. days 1 and 8)
Study: 9499814
Drug: Histamine challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine challenge after beta 2‐agonist pre‐treatment
Study: 26687984
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy without exercise training (Control)
Study: 22706204
Drug: Fluoride concentration
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride concentration at 20 mg/l
Study: 22706204
Drug: Fluoride concentration
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride concentration at 10 mg/l
Study: 22706204
Drug: Fluoride concentration
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride concentration at 5 mg/l
Study: 22706204
Drug: Fluoride concentration
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride concentration at 2.5 mg/l
Study: 22706204
Drug: Fluoride concentration
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride concentration at 0 mg/l
Study: 22706204
Drug: Enamel fluoride
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enamel fluoride uptake (EFU) at 20 mg/l
Study: 22706204
Drug: Enamel fluoride
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enamel fluoride uptake (EFU) at 10 mg/l
Study: 22706204
Drug: Enamel fluoride
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enamel fluoride uptake (EFU) at 5 mg/l
Study: 22706204
Drug: Enamel fluoride
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enamel fluoride uptake (EFU) at 2.5 mg/l
Study: 22706204
Drug: Enamel fluoride
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enamel fluoride uptake (EFU) at 0 mg/l
Study: 16988647
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g xylitol in water
Study: 16988647
Drug: 35 g
Normalized name: SODIUM CHLORIDE 0.135 g in 15 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 g xylitol in water
Study: 16988647
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g erythritol in water
Study: 16988647
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g erythritol in water
Study: 16988647
Drug: 35 g
Normalized name: SODIUM CHLORIDE 0.135 g in 15 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 g erythritol in water
Study: 16988647
Drug: 45 g
Normalized name: SODIUM CHLORIDE 0.045 g in 5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 g sucrose
Study: 18003959
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 microg once daily)
Study: 15286097
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg as a single oral dose
Study: 15286097
Drug: Ximelagatran 36
Normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran 36 mg twice daily for 5 days plus a 40 mg oral dose of atorvastatin on day 4
Study: 9069575
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg i.v. ondansetron
Study: 8260695
Drug: EVDAC regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVDAC regimen (high-dose epirubicin, vincristine, dexamethasone, followed by cyclophosphamide and high-dose cytarabine)
Study: 995040
Drug: Mazindol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mazindol (2 mg one hour before lunch)
Study: 26031908
Drug: Bifidobacterium animalis
Normalized name: Bifidobacterium Animalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium animalis subsp. lactis (BB‐12(®)) at a dose of 10(9) CFU
Study: 24923723
Drug: 1 week
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 week hemifield eye patching and daily sessions of optokinetic stimulation (n=11)
Study: 24923723
Drug: No neglect-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: No neglect-specific treatment (n=10)
Study: 22722637
Drug: Herbal Fufang
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal Fufang (10 g/day, twice per day, n = 101)
Study: 20842051
Drug: CpG loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: CpG loaded virus-like nanoparticles vaccine
Study: 15112937
Drug: Antiepileptic medications
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic medications
Study: 17508528
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (normal neurologic examination, normal test results, no structural brain disease)
Study: 2378793
Drug: Loxiglumide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (2.5 mg kg‐1 in 10 min, followed by 5 mg kg‐1 h‐1 for 200 min)
Study: 141634
Drug: Danazol 50
Normalized name: danazol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol 50 mg daily
Study: 141634
Drug: Danazol 100
Normalized name: danazol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol 100 mg daily
Study: 31735553
Drug: Cytomegalovirus gB-MF59
Normalized name: Cytomegalovirus immunoglobulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytomegalovirus gB-MF59 vaccine
Study: 30095776
Drug: 20‐mL buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20‐mL buffered 1% lidocaine paracervical block
Study: 15766446
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa inhibitors administration
Study: 15766446
Drug: Beta-blockers administration
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers administration
Study: 15766446
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors administration
Study: 15766446
Drug: Statins administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins administration
Study: 9026373
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg Tianeptine (TIA)
Study: 9026373
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg Tianeptine (TIA)
Study: 9026373
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Fluvoxamine (FLU)
Study: 29030268
Drug: Topical vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical vancomycin plus standard of care
Study: 21569111
Drug: 1550-nm non-ablative
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1550-nm non-ablative fractional photothermolysis (NFP) treatment; 4 sessions at 3-week intervals, energy: 15 mJ/MTZ, total density: 1048 MTZs/cm², density per pass: 131 MTZs/cm², total coverage: 20%
Study: 21569111
Drug: 1550-nm non-ablative
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1550-nm non-ablative fractional photothermolysis (NFP) treatment
Study: 16876301
Drug: Dopaminergic agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic agonist (piribedil 50 mg/day)
Study: 15765306
Drug: Quadruple-drug regimen:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple-drug regimen: zidovudine/lamivudine/abacavir/nevirapine
Study: 22414635
Drug: Endotoxin administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endotoxin administration (0.8 ng/kg)
Study: 9836029
Drug: Morphine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (2 mg loading dose, 1 mg in 4 ml bupivacaine 0.125%)
Study: 9836029
Drug: Fentanyl (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (50 micrograms loading dose, 20 micrograms in 4 ml bupivacaine 0.125%)
Study: 3051044
Drug: 2 'Franol'
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 'Franol' tablets
Study: 3051044
Drug: 1 'Franol'
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 'Franol' tablet
Study: 3051044
Drug: 2 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo tablets
Study: 26525410
Drug: WATI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: WATI with messaging further enhanced with personal secure messaging with a tobacco treatment specialist and an online support group (personalized)
Study: 24187859
Drug: Low-dose Huadananshen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Huadananshen mistura (10 mL/day)
Study: 24187859
Drug: High-dose Huadananshen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Huadananshen mistura (20 mL/day)
Study: 15531677
Drug: Triple-fortified salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-fortified salt (TFS) with 30 mug I, 2 mg Fe, and 60 mug vitamin A/g salt
Study: 7930242
Drug: Abbreviated heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abbreviated heparin therapy (n = 118)
Study: 7930242
Drug: 24-hour heparin
Normalized name: Heparine
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24-hour heparin therapy (n = 120)
Study: 26293196
Drug: Preintervention preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preintervention preparation (reading a training manual and demonstration on a teddy bear)
Study: 26293196
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no preintervention preparation)
Study: 22110268
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation with Peg-IFN-α 2b plus ribavirin
Study: 19396424
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard insulin pump regimen)
Study: 16793944
Drug: Oral ethinyl
Normalized name: ethinyl estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ethinyl estradiol (or-EE) 100 microg/day
Study: 16793944
Drug: Testosterone 250
Normalized name: testosterone 250 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone 250 mg twice a week
Study: 16793944
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (CA) 100 mg/day
Study: 16793944
Drug: Transdermal 17beta-estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 17beta-estradiol (td-E) 100 microg twice a week
Study: 14666945
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1 g per day vitamin C plus placebo)
Study: 14666945
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C and E (1 g per day vitamin C plus 200 IU per kg vitamin E)
Study: 8557013
Drug: Rocuronium (0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium (0.45 mg kg‐1)
Study: 8557013
Drug: Atracurium (0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.35 mg kg‐1)
Study: 8557013
Drug: Vecuronium (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.075 mg kg‐1)
Study: 6752961
Drug: ONO 802
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO 802 vaginal suppository (1.0 mg)
Study: 31210499
Drug: Polarity therapy
Normalized name: Adlarity
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polarity therapy (4 sessions)
Study: 26852833
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium (two 50‐mg tablets) and 2% lidocaine gel (3 mL applied on anterior cervical lip and cotton swab soaked in 2% lidocaine gel in cervical canal)
Study: 26852833
Drug: Placebo (tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (tablets and gel)
Study: 10609971
Drug: 15‐mg nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15‐mg nicotine patch plus behavioral treatment
Study: 10609971
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch plus behavioral treatment
Study: 7547655
Drug: Bupivacaine-epinephrine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine-epinephrine (5 micrograms/mL)
Study: 1683191
Drug: Astemizole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole (10 mg daily)
Study: 1683191
Drug: Hydroxyzine hydrochloride
Normalized name: hydroxyzine hydrochloride
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxyzine hydrochloride (25 mg t.i.d.)
Study: 1683191
Drug: Diphenhydramine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (25 mg t.i.d.)
Study: 7185513
Drug: Ethambutol hydrochloride
Normalized name: Ethambutol Hydrochloride
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethambutol hydrochloride tablets (15 mg/kg dosage)
Study: 30900297
Drug: Rectal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal fluid administration (plain water)
Study: 30900297
Drug: Intravenous fluid
Normalized name: Intravenous fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluid administration
Study: 30900297
Drug: Nasogastric fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasogastric fluid administration
Study: 30900297
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment, water and feed withheld)
Study: 27518488
Drug: Flurbiprofen Axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen Axetil (1.0 mg/kg) before anesthesia induction (Group F1)
Study: 24592974
Drug: Double death
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double death prime (combination of subliminal and supraliminal primes)
Study: 22521201
Drug: Customized twice‐daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customized twice‐daily text messages
Study: 15692469
Drug: Pimecrolimus cream
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus cream 1% (twice daily at first signs or symptoms until clearance for 2 years)
Study: 15692469
Drug: Pimecrolimus cream
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus cream 1% (used only in the second year)
Study: 10022424
Drug: Estrogen supplementation
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen supplementation (estradiol valerate, 2 mg daily; n = 7)
Study: 1424269
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 13‐cis‐retinoic acid (0.1% cream)
Study: 3933601
Drug: L-5HTP
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-5HTP
Study: 31330811
Drug: Best magnesium
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best magnesium formulation
Study: 31330811
Drug: Worst magnesium
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Worst magnesium formulation
Study: 28111929
Drug: CDFR0209 (omeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDFR0209 (omeprazole 40 mg + sodium bicarbonate 1100 mg)